Antibiotic Resistance in Children Is Rising Globally, New Study Warns

August 5, 2026 Dr. Michael Lee – Health Editor Health

An escalating global public health challenge is threatening pediatric populations as bacterial pathogens increasingly outpace standard pharmacological defenses, according to a longitudinal study published in July in the journal JAMA Pediatrics. Analyzing bacterial samples collected between 2004 and 2022 across 82 countries, researchers tracked the sobering expansion of antimicrobial resistance in children and projected steep trajectories toward the year 2035. The findings reveal that resistance patterns differ significantly between adults and children, demanding tailored clinical protocols and heightened vigilance from pediatric healthcare providers.

  • A comprehensive analysis published in JAMA Pediatrics evaluated over 106,000 bacterial samples from children and teens aged 0 to 18 across 82 countries, mapping trends from 2004 through 2022 and projecting risks to 2035.
  • Researchers identified critical resistance spikes among pathogens such as Acinetobacter baumannii and Klebsiella, with the highest resistance levels heavily concentrated in intensive care units and resource-limited settings.
  • Antimicrobial resistance contributed to an estimated 840,000 deaths among children under five globally in 2021, underscoring the urgent need to preserve baseline pediatric antibiotic options.

Epidemiological Scope and the JAMA Pediatrics Findings

The study utilized data from the Antimicrobial Testing Leadership and Surveillance database to assess more than 106,000 bacterial samples. Funded and structured to capture a diverse cross-section of global healthcare settings, the dataset spans high-income nations like the United States and the United Kingdom alongside lower-income regions such as Malawi and Uganda. By applying the World Health Organization’s Access, Watch, Reserve (AWaRe) classification system, the investigation mapped how germs have evolved resistance to first-line agents versus last-resort options over a two-decade timeline.

According to study co-author Dr. Yanhong Jessika Hu, a clinical epidemiologist and public health researcher at the Murdoch Children’s Research Institute (MCRI) in Australia, the projections serve as warning scenarios rather than inevitable outcomes. Hu noted to Live Science that the forecasts assume historical patterns will continue without a major change in direction. The analysis established that resistance rates were highest in intensive care units, among children under three years of age presenting with severe infections, and across lower-resource environments.

When examining eight critical and high-priority bacteria designated by the WHO, researchers observed that baseline resistance rates were comparable across high- and low-income nations in 2004, but these curves diverged sharply by 2022. In high-resource countries, resistance to Access antibiotics—recommended as first-choice treatments—dropped from 48% to 29% across the study period. Conversely, in low-income settings, resistance to Access drugs ticked upward slightly from 44% to 47%.

Dr. Penelope Bryant, a clinician-researcher at MCRI, the Royal Children’s Hospital Melbourne, and the University of Melbourne, attributed the decline in high-income regions to substantial investments in controlling methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a notorious pathogen capable of causing painful skin infections and life-threatening complications such as sepsis. By contrast, the crisis is amplified in low-income settings due to compromised sanitation infrastructure and unregulated, over-the-counter access to antibiotics that drives misuse and selective evolutionary pressure.

Modeling Future Risks and Preserving Treatment Options

Looking toward 2035, the mathematical models predict that resistance to Access-category antibiotics will stabilize or decline across most regions. However, the outlook for broader-spectrum Watch and last-resort Reserve drugs is far more concerning. Among the eight priority bacteria, resistance to Watch antibiotics surged from 14% to 24% in high-income nations and from 16% to 48% in low-income countries between 2004 and 2022. Reserve drug resistance climbed correspondingly, moving from 9% to 25% in high-income environments and from 4% to 37% in low-resource settings.

Study warns Antibiotics May Be Becoming Less Effective in Children

Because children inherently possess fewer baseline antibiotic options than adults, preserving the efficacy of existing drugs is paramount. Pediatric infection patterns, metabolic profiles, and exposure frequencies differ starkly from adult populations, meaning adult data cannot safely proxy for pediatric care. Addressing these vulnerabilities requires coordinated systemic intervention, reliable local diagnostics, and strict adherence to antimicrobial stewardship.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this